Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Pediatr Transplant ; 27(3): e14459, 2023 05.
Artículo en Inglés | MEDLINE | ID: mdl-36597218

RESUMEN

BACKGROUND: ABO-incompatible heart transplantation (HTx) has become a standard procedure for children below 2 years of age due to an immunologically immature immune system and associated low isohemagglutinin titers. METHODS: We report a case of an ABO-incompatible HTx (recipient blood group O, donor blood group A) at the age of 5 years and 11 months with a fully matured immune system and previously high isohemagglutinin titers that diminished as a result of human leucocyte antigen (HLA) desensitization therapy with rituximab and immunoglobulins. RESULTS: The anti-A titer at the time of HTx was 1:16 with post-transplant isoagglutinin titers never exceeding 1:4 without any signs of rejection with now 3 years of post-HTx follow-up. CONCLUSIONS: ABO isohemagglutinin titers should be routinely assessed in children undergoing desensitization therapy since ABOi transplantation can be considered in selected cases to expand the donor pool with the option of crossing the ABO barrier to find a better-matched allograft.


Asunto(s)
Trasplante de Corazón , Hemaglutininas , Humanos , Niño , Adolescente , Preescolar , Donadores Vivos , Rituximab/uso terapéutico , Incompatibilidad de Grupos Sanguíneos , Rechazo de Injerto , Sistema del Grupo Sanguíneo ABO
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA